EyePoint Pharmaceuticals (PV3B) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PV3B Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

EyePoint

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PV3B Stock 12 Month Forecast

Average Price Target

€36.06

▲(193.17% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is €36.06 with a high forecast of €59.63 and a low forecast of €17.54. The average price target represents a 193.17% change from the last price of €12.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","33":"€33","60":"€60","19.5":"€19.5","46.5":"€46.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59.62579524,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€59.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.06045337125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€36.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5369986,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,19.5,33,46.5,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,15.755830403076923,19.411660806153847,23.06749120923077,26.723321612307693,30.37915201538462,34.03498241846154,37.690812821538465,41.346643224615384,45.00247362769231,48.65830403076924,52.31413443384616,55.96996483692308,{"y":59.62579524,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.943111797788461,15.786223595576923,17.629335393365384,19.472447191153844,21.315558988942307,23.158670786730767,25.001782584519226,26.84489438230769,28.688006180096153,30.531117977884612,32.37422977567307,34.21734157346153,{"y":36.06045337125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,12.51823066153846,12.936461323076923,13.354691984615384,13.772922646153846,14.191153307692307,14.60938396923077,15.02761463076923,15.445845292307693,15.864075953846154,16.282306615384616,16.70053727692308,17.118767938461538,{"y":17.5369986,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.696,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.238,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.536,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.665,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.165,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.285,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.955,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€59.63

Average Price Target€36.06

Lowest Price Target€17.54

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Daniil Gataulin

Chardan Capital

€25.43→€57

Buy

363.38%

Upside

Reiterated

07/01/26

EyePoint price target raised to $65 from $29 at ChardanEyePoint price target raised to $65 from $29 at Chardan

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€26.31

Buy

113.87%

Upside

Reiterated

06/25/26

Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Yatin Suneja

Guggenheim

€59.63

Buy

384.76%

Upside

Reiterated

06/24/26

Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

Graig Suvannavejh

Mizuho Securities

€31.57

Buy

156.64%

Upside

Reiterated

06/22/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Nuvectis Pharma (NASDAQ: NVCT)

Debanjana Chatterjee

JonesTrading

€37.7

Buy

206.54%

Upside

Reiterated

06/18/26

Analysts' Top Healthcare Picks: Voyager Therapeutics (VYGR), EyePoint Pharmaceuticals (EYPT)

Lisa Walter

RBC Capital

€34.2→€32.44

Buy

163.77%

Upside

Reiterated

05/07/26

RBC Capital Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yi Chen

H.C. Wainwright

€26.31

Buy

113.87%

Upside

Reiterated

05/07/26

Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress

Tara Bancroft

TD Cowen

€17.54

Buy

42.58%

Upside

Reiterated

05/06/26

Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)

Tessa Romero

J.P. Morgan

€28.94

Buy

135.25%

Upside

Reiterated

03/10/26

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Yigal Nochomovitz

Citi

€27.18→€30.69

Buy

149.51%

Upside

Reiterated

03/09/26

EyePoint price target raised to $35 from $31 at CitiEyePoint price target raised to $35 from $31 at Citi

Greg Harrison

Scotiabank

€15.78

Buy

28.32%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Daniil Gataulin

Chardan Capital

€25.43→€57

Buy

363.38%

Upside

Reiterated

07/01/26

EyePoint price target raised to $65 from $29 at ChardanEyePoint price target raised to $65 from $29 at Chardan

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€26.31

Buy

113.87%

Upside

Reiterated

06/25/26

Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Yatin Suneja

Guggenheim

€59.63

Buy

384.76%

Upside

Reiterated

06/24/26

Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

Graig Suvannavejh

Mizuho Securities

€31.57

Buy

156.64%

Upside

Reiterated

06/22/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Nuvectis Pharma (NASDAQ: NVCT)

Debanjana Chatterjee

JonesTrading

€37.7

Buy

206.54%

Upside

Reiterated

06/18/26

Analysts' Top Healthcare Picks: Voyager Therapeutics (VYGR), EyePoint Pharmaceuticals (EYPT)

Lisa Walter

RBC Capital

€34.2→€32.44

Buy

163.77%

Upside

Reiterated

05/07/26

RBC Capital Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yi Chen

H.C. Wainwright

€26.31

Buy

113.87%

Upside

Reiterated

05/07/26

Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress

Tara Bancroft

TD Cowen

€17.54

Buy

42.58%

Upside

Reiterated

05/06/26

Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)

Tessa Romero

J.P. Morgan

€28.94

Buy

135.25%

Upside

Reiterated

03/10/26

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Yigal Nochomovitz

Citi

€27.18→€30.69

Buy

149.51%

Upside

Reiterated

03/09/26

EyePoint price target raised to $35 from $31 at CitiEyePoint price target raised to $35 from $31 at Citi

Greg Harrison

Scotiabank

€15.78

Buy

28.32%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months

Graig SuvannavejhMizuho Securities

Success Rate

14/23 ratings generated profit

Average Return

+13.60%

Copying Graig Suvannavejh's trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +13.60% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

12/16 ratings generated profit

Average Return

+38.22%

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +38.22% per trade.

2 Years

Debanjana ChatterjeeJonesTrading

Success Rate

13/16 ratings generated profit

Average Return

+39.65%

Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +39.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PV3B Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PV3B has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PV3B average Analyst price target in the past 3 months is 36.06.

Each month's total comprises the sum of three months' worth of ratings.

PV3B Financial Forecast

PV3B Earnings Forecast

Next quarter’s earnings estimate for PV3B is -€0.83 with a range of -€1.05 to -€0.68. The previous quarter’s EPS was -€0.87. PV3B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PV3B has Performed in-line its overall industry.

PV3B Sales Forecast

Next quarter’s sales forecast for PV3B is €335.83K with a range of €0.00 to €613.79K. The previous quarter’s sales results were €610.29K. PV3B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PV3B has Performed in-line its overall industry.

PV3B Stock Forecast FAQ

What is DE:PV3B’s average 12-month price target, according to analysts?

Based on analyst ratings, Eyepoint Pharma’s 12-month average price target is 36.06.

What is DE:PV3B’s upside potential, based on the analysts’ average price target?

Eyepoint Pharma has 193.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eyepoint Pharma a Buy, Sell or Hold?

Eyepoint Pharma has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Eyepoint Pharma’s share price target?

The average share price target for Eyepoint Pharma is 36.06. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €59.63 ,and the lowest forecast is €17.54. The average share price target represents 193.17% Increase from the current price of €12.3.

What do analysts say about Eyepoint Pharma?

Eyepoint Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Eyepoint Pharma?

To buy shares of DE:PV3B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

EyePoint Pharmaceuticals (PV3B) Stock Forecast & Price Target

PV3B Analyst Ratings

PV3B Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering EyePoint Pharmaceuticals

PV3B Analyst Recommendation Trends

PV3B Financial Forecast

PV3B Earnings Forecast

PV3B Sales Forecast

PV3B Stock Forecast FAQ

Detailed List of Analyst Forecasts